T 1399/04 (Combination therapy HCV/SCHERING) of 25.10.2006
- European Case Law Identifier
- ECLI:EP:BA:2006:T139904.20061025
- Date of decision
- 25 October 2006
- Case number
- T 1399/04
- Petition for review of
- -
- Application number
- 99303729.0
- IPC class
- A61K 38/21
- Language of proceedings
- English
- Distribution
- Distributed to board chairmen (C)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis C infection
- Applicant name
- SCHERING CORPORATION
- Opponent name
- 01. Alfa Wassermann S.p.A.
02. Teva Pharmaceutical Industries Ltd.
03. Sandoz GmbH
04. Krauss, Jan B. - Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 111(1) 1973European Patent Convention Art 113(1) 1973European Patent Convention Art 123(2) 1973European Patent Convention Art 52(4) 1973European Patent Convention Art 54 1973European Patent Convention Art 87 1973European Patent Convention Art 88 1973European Patent Convention Art 89 1973European Patent Convention R 67 1973
- Keywords
- Substantial procedural violation - (yes)
Reimbursement of the appeal fee - (yes)
Admissibility of late-filed documents - (yes)
Added subject-matter - (no)
Not patentable invention - (no)
Priority, novelty - (yes) - Catchword
- -
ORDER
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the department of first instance for further prosecution.
3. The reimbursement of the appeal fees is ordered.